Biotechnology - 12th European Congress.
Neubauer
Peter
P
University of Oulu, Department of Process & Environmental Engineering, Bioprocess Engineering Laboratory, Finland. peter.neubauer@oulu.fi
Mursula
Anu
A
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use; D001709:Biotechnology / Q000379:methods* / Q000639:trends*; D017326:Clinical Trials, Phase III as Topic; D003888:Desensitization, Immunologic / Q000379:methods; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D005167:Factor VII / Q000494:pharmacology / Q000627:therapeutic use; D015942:Factor VIIa; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007518:Isoantibodies / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use; D000069450:Liraglutide; D051379:Mice; D004364:Pharmaceutical Preparations / Q000737:chemistry; D011487:Protein Conformation; D040901:Proteomics / Q000379:methods / Q000639:trends; D034741:RNA, Small Interfering / Q000627:therapeutic use; D051381:Rats; D043562:Receptors, G-Protein-Coupled / Q000502:physiology; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D013234:Stem Cells / Q000473:pathology / Q000502:physiology; D023822:Tissue Engineering / Q000379:methods / Q000639:trends
D000911:Antibodies, Monoclonal; D007518:Isoantibodies; D004364:Pharmaceutical Preparations; C033242:RH-antibodies; D034741:RNA, Small Interfering; D043562:Receptors, G-Protein-Coupled; D011994:Recombinant Proteins; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa